

COVINGTON & BURLING LLP

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202.662.6000
FAX 202.662.6291
WWW.COV.COM

BEIJING
BRUSSELS
LONDON
NEW YORK
SAN DIEGO
SAN FRANCISCO
SILICON VALLEY
WASHINGTON

June 3, 2011

BY EMAIL AND U.S. MAIL

Karen Midthun, M.D.
Presiding Officer
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike
Rockville, Maryland 20852-1448

Re: Docket No. FDA-2010-N-0621; Avastin®

Dear Dr. Midthun:

Provided below is the list of representatives who will ask questions on behalf of Genentech, Inc. at the June 28-29 hearing.

1. Philippe Bishop, M.D., Vice President, Clinical Development - Avastin, Genentech, Inc.
2. Jeff Helterbrand, Ph.D., Vice President, Global Head of Biostatistics, Genentech, Inc.
3. Paul W. Schmidt, Covington & Burling LLP

Thank you.

Sincerely,



Michael S. Labson
Paul W. Schmidt

Covington & Burling LLP
Counsel for Genentech, Inc.

cc: Donald Beers, Office of the Chief Counsel, Food and Drug Administration
Laurie Lenkel, Office of the Ombudsman, Food and Drug Administration
Carla Cartwright, Office of the Chief Counsel, Food and Drug Administration
Abigail Brandel, Office of the Chief Counsel, Food and Drug Administration